Healthcare
Entera Bio Ltd.(ENTX)
Live Price
Offline$1.20
+1.69% today
1Y Change
-39.09%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -76.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Entera Bio Ltd. (ENTX) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $1.20 and down 39.1% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -76.8%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -76.8%, EPS 0.0%, free cash flow -9.6% with operating margin -27450.0% and ROIC -218.8%. Valuation already assumes a fairly strong business story at price/sales 1287.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ENTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-76.8% vs +7.6% peer median
Operating Margin
Below sector median
-27450.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -76.8% and EPS is at 0.0%, with operating margin around -27450.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -10.0% | -3.1% | -7.7% |
2026 Mar 27, 2026 | +22.2% | -11.5% | +5.3% | +1.8% |
2025 Nov 14, 2025 | +22.2% | -1.1% | -6.6% | -23.2% |
Benchmark Edge
ENTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ENTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ENTX Max Drawdown
-68.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ENTX and SPY.
Company Overview
Entera Bio Ltd.
NASDAQ Capital Market
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
- Leadership
- Miranda J. Toledano
- IPO Date
- Jun 28, 2018
- Employees
- 18
- Street Address
- Kiryat Hadassah Minrav Building
- Mailing
- Jerusalem, 9112002
- Region
- Jerusalem, IL
- Reporting Currency
- USD
- Investor Line
- 972 2 532 7151
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1287.7
- Price/Book
- 4.1
Growth
- Revenue
- -76.8%
- EPS
- 0.0%
- Free Cash Flow
- -9.6%
Profitability
- Gross Margin
- -35.7%
- Operating Margin
- -27450.0%
- Net Margin
- -27235.7%
- ROE
- -70.4%
- ROIC
- -218.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 3.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.